Abstract
* Reslizumab (Cinqair), a new human monoclonal antibody, has been approved to treat severe asthma in adults. Given intravenously, the drug is used as adjunct therapy, in conjunction with inhaled corticosteroids, to reduce the frequency of asthma exacerbations, relieve asthma symptoms, and improve lung function in patients with elevated blood eosinophil levels.
* Like all monoclonal antibodies, it carries a risk of anaphylaxis.